BioBusiness

Of all the protein products on the US market, at most 75 are likely to become genericized.

A powerful film will have a hundred times the impact of a touchy-feely commercial.

Minimum disruption and maximum gain result when adopting a distributed process control and data management system for a cell culture and fermentation lab.

Australia's pharmaceutical industry as a whole turns over approximately US$10.7 billion a year and spends some US$384 million annually on research and development.

The above statement reflects the opinion of a growing number of US governors and key state lawmakers.

. . . Popular consortium meetings have focused on successful use of tools to drive improvement in cycle time reduction, deviation reduction, and improved production efficiency.

Like a snowball rolling down Mt. Everest, stem- cell research was gaining momentum, not only in political and medical arenas, but on Wall Street, too.

On June 13, 2005, in Merck KgaA v. Integra Lifesciences I, Ltd., the US Supreme Court ruled unanimously that the exemption to patent infringement outlined in Title 35, Section 271(e)(1) of the US Code extends to all uses of patented inventions reasonably related to the development and submission of any information under the Food, Drug, and Cosmetic Act, including preclinical studies. In practice, this means that the exemption will allow companies to use other firms' patented compounds for experimentation on drugs that are not ultimately the subject of a submission to the Food and Drug Administration.

These latest pressures on technology relate not only to the need for improved manufacturing productivity and shorter development times, but also to the need to create smarter manufacturing operations

How much of an impact does patent reform, real or imagined, have on biopharmaceutical stocks?

The moral to the story is that the human body is immensely more complex than any computer that we've been able to dream up.

Through a series of collaborative activities with other industry groups, the Irish BioIndustry Association supports the continued development of the biotech sector in Ireland.

Ireland's dynamic life sciences industry attracts investors, both foreign and domestic, and lures its brightest minds back home.

As companies evolve, they often must select new locations where they can centralize or expand their operations. This can be a daunting challenge that demands consideration of numerous factors.

With a bright new future following restructuring, Dublin-based Elan sees former executives establish exciting new businesses in Ireland, while it continues its own strong R&D program.

The EU Framework Program has operated for the last twenty years, dedicating large sums of funding over five-year periods, all the time aiming to achieve scientific excellence, improved competitiveness, and innovation through promoting increased cooperation between researchers and industry across Europe.

Ireland's Forward-Thinking Business Support Strategy Encourages Research Funding and Fast-Track Company Growth

Venture capital activity in Ireland grew 25.7% in the first half of 2005 compared with the same period in 2004. New life-sciences venture capital funds have been established and existing firms have ramped up their activity in the sector.

The Irish Minister for Enterprise, Trade, and Employment supports and encourages biotech research and development.

The creation, dissemination, and exploitation of knowledge are the keys to unlocking the potential of Ireland's economy.

The cell density achieved in a CELLine bioreactor is typically 1 to 2 orders of magnitude higher than in a conventional culture vessel

Doctors can charge up to $500 per hour to discuss the pros and cons of clinical drug trials.

According to a 2005 study by the American Academy of Neurology, donepezil may improve the memory of Alzheimers patients and those suffering with multiple sclerosis.

Operating costs are the white-hot issue in the boardrooms of our life sciences clients and they tend to rule the site selection process. A soft economy, worldwide trade competition, drug cost containment pressures from the US government, and a lean and mean message sent by the venture capital community mean that quantitative factors that focus on the cost of doing business are trumping qualitative lifestyle factors, especially when evaluating sites for a new biopharmaceutical facility.

The ripple effects of 9/11 are still being felt, creating changes among individuals, businesses, and government organizations. The biotech community is no different; companies are taking a new look at the way they do business and shifting their focuses in response to new opportunities presented by federal preparedness programs. In 2004, President Bush signed "Project BioShield," a bill that made $5.6 billion in federal funds available over a 10-year period to develop countermeasures against chemical, biological, radiological, or nuclear attack. An additional $2.5 billion was added to the initiative in 2005. Numerous grants and contracts have already been awarded to companies developing innovative prophylactic measures, treatments, and diagnostic tools to be used in the event of a biological attack.